All major European markets were trading lower, except Spain’s that edged up 0.1% ... European Medicines Agency backed the use ...

Stock futures edged lower as the dust settled after Thursday's rally, and bond yields traded just shy of two week highs. Investors will see option contracts tied to more than $5 trillion in tradeable ...

(Reuters) - European shares slipped on Friday after a rally in the previous session spurred by U.S. Federal Reserve's ...

A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney cancer.

To donate by check, phone, or other method, see our More Ways to Give page. Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

A new study found that women using the weight loss drug tirzepatide (Mounjaro) lost more weight than men, but experienced ...

A PILL from the makers of Ozempic and Wegovy leads to faster and longer-lasting weight loss than the popular ‘skinny jabs’, a ...

Roche is holding out hopes that its injectable obesity prospect could eventually demonstrate 25% weight loss in late-stage ...

"EASD 2024: Novo Nordisk’s Saxenda shows weight loss in children" was originally created and published by Pharmaceutical ...

A new weight loss pill developed by the maker of Ozempic and Wegovy helped overweight and obese people lose up to 13% of ...

Novo Nordisk (NVO) stock rises after full results from an early-stage trial of weight-loss pill amycretin. Read more here.

Danish pharma giant Novo Nordisk has reported promising data on its new weight loss pill, which has been shown to lower body ...